Glucokinase activators for diabetes therapy: May 2010 status report

Diabetes Care

Volumn 34, Issue SUPPL. 2, 2011, Pages

  Matschinsky, Franz M ^a   Zelent, Bogumil ^a   Doliba, Nicolai ^a   Li, Changhong ^a,b   Vanderkooi, Jane M ^a   Naji, Ali ^a   Sarabu, Ramakanth ^c   Grimsby, Joseph ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c Hoffman La Roche Department of Metabolic Diseases   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ANTIDIABETIC AGENT; ARRY 403; CALCIUM; CALCIUM CHANNEL L TYPE; GLUCAGON; GLUCOKINASE; GLUCOKINASE ACTIVATOR; GLUCOSE; INSULIN; NUCLEAR PROTEIN; PIRAGLIATIN; PROTEIN BAD; PROTEIN GKRP; UNCLASSIFIED DRUG;

CALCIUM CELL LEVEL; COMPETITIVE INHIBITION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME STRUCTURE; GENE; GENE MUTATION; GLUCAGON RELEASE; GLUCOKINASE GENE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE OXIDATION; GLYCOLYSIS; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; LIVER CELL; MULTIPLE DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXYGEN CONSUMPTION; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; REVIEW; SINGLE DRUG DOSE; ARTICLE; ENZYMOLOGY; METABOLISM;

DIABETES MELLITUS, TYPE 2; GLUCOKINASE; GLUCOSE; HUMANS;

EID: 79959798614     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-s236     Document Type: Review

References (56)

1. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-795
2. Wild S, Roglic G, Green A, Sicree R, King H. Global preference of diabetes. Diabetes Care 2004;27:1047-1053
3. Matschinsky FM. Assessing the potential of glucokinase activators in diabetes therapy. Nat Rev Drug Discov 2009;8:399-416
4. Grimsby J, Sarabu R, Corbett WL, et al. Allosteric activators of glucokinase: potential role in diabetes therapy. Science 2003;301:370-373 (Pubitemid 36877072)
5. Zhi J, Zhai S, Mulligan ME, Grimsby J, Arbet-Engels C, Boldrin M, Balena R. A novel glucokinase activator RO4389620 improved fasting and postprandial plasma glucose in type 2 diabetic patients (Abstract). Diabetologia 2008;51(Suppl. 1):S23
6. Bonadonna RC, Kapitza C, Heinse T, et al. Glucokinase activator RO4389620 improves beta cell function and plasma glucose indexes in patients with type 2 diabetes (Abstract). Diabetologia 2008;51(Suppl. 1):S371
7. Sarabu R, Grimsby J. Targeting glucokinase activation for the treatment of type 2 diabetes: a status review. Curr Opin Drug Discov Devel 2005;8:631-637 (Pubitemid 41224126)
8. Guertin KR, Grimsby J. Small molecule glucokinase activators as glucose lowering agents: a new paradigm for diabetes therapy. Curr Med Chem 2006;13:1839-1843 (Pubitemid 43871760)
9. Matschinsky FM, Magnuson MA, Zelent D, et al. The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy. Diabetes 2006;55:1-12 (Pubitemid 43343293)
10. Zhai S, Mulligan ME, Grimsby J, Arbet-Engels C, Boldrin M, Balena R, Zhi J. Phase I assessment of a novel glucose activator RO4389620 in healthy male volunteers (Abstract). Diabetologia 2008;51(Suppl. 1):S372
11. Coghlan M, Leighton B. Glucokinase activators in diabetes management. Expert Opin Investig Drugs 2008;17:145-167 (Pubitemid 351578197)
12. Sarabu R, Berthel SJ, Kester RF, Tilley JW. Glucokinase activators as new type 2 diabetes therapeutic agents. Expert Opin Ther Pat 2008;18:759-768
13. Pal M. Recent advances in glucokinase activators for the treatment of type 2 diabetes. Drug Discov Today 2009;14:784-792
14. Matschinsky FM. Banting Lecture 1995. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm. Diabetes 1996;45:223-241 (Pubitemid 26045806)
15. Kamata K, Mitsuya M,Nishimura T, Eiki J, Nagata Y. Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase. Structure 2004;12:429-438 (Pubitemid 38353064)
16. Dunten P, Swain A, Kammlott U, et al. Crystal structure of human liver glucokinase bound to a small molecule allosteric activator in glucokinase and glycemic disease: from basics to novel therapeutics. Front Diabetes 2004;16:145-154
17. Efanov AM, Barrett DG, Brenner MB, et al. A novel glucokinase activator modulates pancreatic islet and hepatocyte function. Endocrinology 2005;146:3696-3701 (Pubitemid 41175734)
18. Zelent B, Odili S, Buettger C, et al. Sugar binding to recombinant wild-type and mutant glucokinase monitored by kinetic measurement and tryptophan fluorescence. Biochem J 2008;413:269-280
19. Meglasson MD, Matschinsky FM. New perspectives on pancreatic islet glucokinase. Am J Physiol 1984;246:E1-E13 (Pubitemid 14117087)
20. Meglasson MD, Matschinsky FM. Pancreatic islet glucose metabolism and regulation of insulin secretion. Diabetes Metab Rev 1986;2:163-214 (Pubitemid 16009507)
21. Bedoya FJ, Matschinsky FM, Shimizu T, O'Neil JJ, Appel MC. Differential regulation of glucokinase activity in pancreatic islets and liver of the rat. J Biol Chem 1986;261:10760-10764 (Pubitemid 17194863)
22. Postic C, Shiota M, Magnuson MA. Cell-specific roles of glucokinase in glucose homeostasis. Recent Prog Horm Res 2001;56:195-217
23. Iynedjian PB. Molecular physiology of mammalian glucokinase. Cell Mol Life Sci 2009;66:27-42
24. Newgard CB, Matschinsky FM. Substrate control of insulin release: the endocrine system. Vol II. The endocrine pancreas and regulation of metabolism. In Handbook of Physiology. Jefferson J, Cherrington A, Eds. Oxford, Oxford University Press, 2001, p. 125-151
25. Henquin JC. Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes 2000;49:1751-1760
26. Prentki M, Matschinsky FM. Ca2+, cAMP, and phospholipid-derived messengers in coupling mechanisms of insulin secretion. Physiol Rev 1987;67:1185-1248 (Pubitemid 18003171)
27. Gromada J, Franklin I, Wollheim CB. α-cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr Rev 2007;28:84-116 (Pubitemid 46220851)
28. Li C, Liu C, Nissim I, et al. The role of glycine and gamma-hydoxybutyrate in the regulation of glucagon secretion in human islets. 2009 Spring Symposium and Kroc Lecture, University of Pennsylvania, 11 March 2009
29. Agius L. The physiological role of glucokinase binding and translocation in hepatocytes. Adv Enzyme Regul 1998;38:303-331 (Pubitemid 28381397)
30. Agius L. Glucokinase and molecular aspects of liver glycogen metabolism. Biochem J 2008;414:1-18
31. Vandercammen A, Van Schaftingen E. The mechanism by which rat liver glucokinase is inhibited by the regulatory protein. Eur J Biochem 1990;191:483-489 (Pubitemid 20233766)
32. Vandercammen A, Van Schaftingen E. Competitive inhibition of liver glucokinase by its regulatory protein. Eur J Biochem 1991;200:545-551
33. Detheux M, Vandercammen A, Van Schaftingen E. Effectors of the regulatory protein acting on liver glucokinase: a kinetic investigation. Eur J Biochem 1991;200:553-561
34. Veiga-da-Cunha M, Van Schaftingen E. Identification of fructose 6-phosphate- and fructose 1-phosphate-binding residues in the regulatory protein of glucokinase. J Biol Chem 2002;277:8466-8473 (Pubitemid 34968308)
35. Osbak KK, Colclough K, Saint-Martin C, et al. Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia. Hum Mutat 2009;30:1512-1526
36. Veiga-da-Cunha M, Courtois S, Michel A, Gosselain E, Van Schaftingen E. Amino acid conservation in animal glucokinases: identification of residues implicated in the interaction with the regulatory protein. J Biol Chem 1996;271:6292-6297 (Pubitemid 26095436)
37. Wilms B, Ben-Ami P, Söling HD. Hepatic enzyme activities of glycolysis and gluconeogenesis in diabetes ofman and laboratory animals. Horm Metab Res 1970;2:135-141
38. Caro JF, Triester S, Patel VK, Tapscott EB, Frazier NL, Dohm GL. Liver glucokinase: decreased activity in patients with type II diabetes. Horm Metab Res 1995;27:19-22
39. Torres TP, Catlin RL, Chan R, et al. Restoration of hepatic glucokinase expression corrects hepatic glucose flux and normalizes plasma glucose in zucker diabetic fatty rats. Diabetes 2009;58:78-86
40. Fyfe MCT, White JR, Taylor A, et al. Glucokinase activator PSN-GK1 displays enhanced antihyperglycaemic and insulinotropic actions. Diabetologia 2007;50:1277-1287 (Pubitemid 46701554)
41. Leighton B, Atkinson A, Coope GJ, Coghlan MP. Improved glycemic control after sub-acute administration of a glucokinase activator to male Zucker (fa/fa) rats (Abstract). Diabetes 2007;56:0377OR
42. Sorhede Winzell M, Coghlan MP. Glucokinase activation reduces glycemia and improves glucose tolerance in mice with high-fat diet-induced insulin resistance (Abstract). Diabetes 2007;56:1482P
43. Nakamura A, Takamoto I, Kubota N. Impact of small molecule glucokinase activator on glucose metabolism in response to high fat diet in mice with β-cell specific haploinsufficiency of glucokinase gene (Abstract). Diabetes 2007;56:529P
44. Anderka O, Boyken J, Aschenbach U, Batzer A, Boscheinen O, Schmoll D. Biophysical characterization of the interaction between hepatic glucokinase and its regulatory protein: impact of physiological and pharmacological effectors. J Biol Chem 2008;283:31333-31340
45. Danial NN, Gramm CF, Scorrano L, et al. BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis. Nature 2003;424:952-956 (Pubitemid 37051687)
46. Danial NN, Walensky LD, Zhang C-Y, et al. Dual role of proapoptotic BAD in insulin secretion and beta cell survival. Nat Med 2008;14:144-153 (Pubitemid 351214557)
47. Arden C, Baltrusch S, Agius L. Glucokinase regulatory protein is associated with mitochondria in hepatocytes. FEBS Lett 2006;580:2065-2070
48. Miwa I, Toyoda Y, Yoshie S. Glucokinase and glycemic disease: from basics to novel therapeutics. Front Diabetes 2004;16:350-359
49. Baltrusch S, Wu C, Okar DA, Tiedge M, Lange AJ. Glucokinase and glycemic disease: from basics to novel therapeutics. Front Diabetes 2004;16:262-274
50. Kassem S, Bhandari S, Rodríguez-Bada P, et al. Large islets, beta-cell proliferation, and a glucokinase mutation. N Engl J Med 2010;362:1348-1350
51. Terauchi Y, Takamoto I, Kubota N, et al. Glucokinase and IRS-2 are required for compensatory β cell hyperplasia in response to high-fat diet-induced insulin resistance. J Clin Invest 2007;117:246-257 (Pubitemid 46048470)
52. Takamoto I, Terauchi Y, Kubota N, Ohsugi M, Ueki K, Kadowaki T. Crucial role of insulin receptor substrate-2 in compensatory β-cell hyperplasia in response to high fat diet-induced insulin resistance. Diabetes Obes Metab 2008;10 (Suppl. 4):147-156
53. Doliba N, Qin W, Najafi H, et al. Piragliatin, an allosteric activator of glucokinase, increases glucose-induced respiration and insulin release of pancreatic islets from type 2 diabetics. Poster presented at University of Pennsylvania IDOM/DERC Spring Symposium, 10 March 2010
54. Brocklehurst KJ, Payne VA, Davies RA, et al. Stimulation of hepatocyte glucose metabolism by novel small molecule glucokinase activators. Diabetes 2004;53:535-541 (Pubitemid 38270620)
55. Grimsby J, Matschinsky FM, Grippo JF. Glucokinase and glycemic disease: from basics to novel therapeutics. Front Diabetes 2004;16:360-378
56. News release of 10 August 2009; thaugeto@arraybiopharma.com